The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms

详细信息    查看全文

• 作者：Maria Gabriela Berzoti-Coelho^a ; ¹ ; Aline Fernanda Ferreira^a ; ^b ; ¹ ; ^{alineferreira591@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Natalia de Souza Nunes^a ; Mariana Tomazini Pinto^a ; ^b ; Maurí ; cio Cristiano Rocha Jú ; nior^a ; ^b ; Belinda Pinto Simõ ; es^b ; ^c ; Carlos Martí ; nez-A^d ; Elizabeth Xisto Souto^e ; Rodrigo Alexandre Panepucci^b ; ^c ; Dimas Tadeu Covas^b ; ^c ; Simone Kashima^a ; ^b ; Fabí ; ola Attié ; Castro^a ; ^b
• 关键词：Myeloproliferative Neoplasms ; DIDO ; Apoptosis ; JAK2V617F ; BCR-ABL1
• 刊名：Blood Cells, Molecules and Diseases
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：59
• 期：Complete
• 页码：25-30
• 全文大小：533 K

文摘

Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) are Myeloproliferative Neoplasms (MPN) characterized by clonal myeloproliferation without cell maturation impairment. CML pathogenesis is associated with the Ph chromosome leading to BCR-ABL tyrosine-kinase constitutive expression. The Ph negative MPN (PV, ET and PMF) are characterized by the mutation JAK2^V617F of the JAK2 protein in the auto-inhibitory JH2 domain, which is found in most PV patients and in approximately half of ET and PMF patients. Considerable effort is being made to understand the role of JAK2^V617F at the MPN initiation and to clarify the pathogenesis and apoptosis resistance in CML, PV, ET and PMF patients. In the present investigation, we evaluated the Death Inducer-Obliterator (DIDO) (variants DIDO 1, 2 and 3) levels in CML, PV, ET and PMF patients. Our data reported the DIDO 1, 2 and 3 differential expressions in Myeloproliferative Neoplasms.